Simple jQuery Dropdowns

Browsing by Author Universitatsklinikum Jena und Medizinische Fakultat

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)
1-May-2016Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialA. Hochhaus; G. Saglio; T. P. Hughes; R. A. Larson; D. W. Kim; S. Issaragrisil; P. D. Le Coutre; G. Etienne; P. E. Dorlhiac-Llacer; R. E. Clark; I. W. Flinn; H. Nakamae; B. Donohue; W. Deng; D. Dalal; H. D. Menssen; H. M. Kantarjian; Universitatsklinikum Jena und Medizinische Fakultat; Università degli Studi di Torino; The University of Adelaide; University of Chicago; The Catholic University of Korea; Mahidol University; Charité – Universitätsmedizin Berlin; Institut Bergonie; Universidade de Sao Paulo - USP; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Sarah Cannon Research Institute; Osaka City University; Novartis Pharmaceuticals Corporation; Novartis International AG; University of Texas MD Anderson Cancer Center
17-Jun-2010Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio; Dong Wook Kim; Surapol Issaragrisil; Philipp Le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E. Clark; Andreas Hochhaus; Timothy P. Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A. Larson; Hagop M. Kantarjian; Universita degli Studi di Torino; The Catholic University of Korea; Mahidol University; Charité – Universitätsmedizin Berlin; Institut Bergonie; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti; Universidade Federal do Parana; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Universitatsklinikum Jena und Medizinische Fakultat; Royal Adelaide Hospital; Novartis International AG; Novartis Pharmaceuticals; University of Chicago; University of Texas MD Anderson Cancer Center